Exploring the Feasibility of Silk Fibroin Surgical Mesh in Rotator Cuff Tears Repair Enhancement
1 other identifier
interventional
20
1 country
1
Brief Summary
Rotator cuff tears result in shoulder joint pain and movement disorders, affecting patients' daily lives. The incidence rate rises with age and can be as high as 54% among people over 60 years old. Most rotator cuff tears are unable to heal spontaneously, and the tear area may gradually expand over time. Currently, the main surgical treatment for rotator cuff tears is to use suture anchors to stitch the rotator cuff tendon tissue back to the original anatomical insertion point. Large rotator cuff tears are often accompanied by fat infiltration and tendon retraction. When forcefully sutured, the tension is relatively high, which may lead to non-healing and re-tearing of the rotator cuff. Research indicates that the re-tear rate after rotator cuff tear repair is 20% - 30%, and this probability can reach 40% - 50% for large rotator cuff tears. For these irreparable and large tears, rotator cuff repair typically requires patch augmentation techniques. Surgeries are based on restoring the force couple effect of the rotator cuff as much as possible and covering it with repair materials to achieve reinforcement. Silk fibroin surgical mesh is made of silk fibroin which has good biocompatibility and can be generally placed in the area of rotator cuff tears that cannot be repaired through conventional surgeries. By providing support to the injured rotator cuff tissue, it improves the repair effect. It can reestablish the integrity of the rotator cuff, reducing mechanical tension at the repair site and maintaining the stability of the glenohumeral joint. Besides, it can also promote tissue healing, and cell infiltration and growth, thereby facilitating the biological repair of the injured rotator cuff and reducing the occurrence of postoperative re-tears.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for phase_2
Started Dec 2024
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
December 19, 2024
CompletedStudy Start
First participant enrolled
December 19, 2024
CompletedFirst Posted
Study publicly available on registry
January 9, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 19, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
December 19, 2026
ExpectedJanuary 9, 2025
December 1, 2024
1 year
December 19, 2024
January 8, 2025
Conditions
Outcome Measures
Primary Outcomes (1)
Re-tear rate at 12 months postoperatively
From enrollment to the end of treatment at 12 months
Secondary Outcomes (6)
Re-tear rate at 6 months postoperatively
From enrollment to 6 months after surgery
Constant-Murley Score postoperatively
From enrollment to the end of treatment at 12 months
Oxford Shoulder Score postoperatively
From enrollment to the end of treatment at 12 months
Degree of muscle atrophy
From enrollment to the end of treatment at 12 months
Fatty infiltration grading
From enrollment to the end of treatment at 12 months
- +1 more secondary outcomes
Study Arms (1)
using silk fibroin surgical mesh to enhance rotator cuff tear repair
EXPERIMENTALInterventions
This product is a mesh patch made of mulberry silk by warp knitting and degumming. The main component is fibroin protein
Eligibility Criteria
You may qualify if:
- Preoperative:
- Age range of 50-75 years old (inclusive), gender not limited;
- Patients who require surgery due to rotator cuff tears detected by clinical and MRI examination;
- Evaluated as type IV and above according to Sugaya classification criteria;
- Patients with persistent or recurrent pain in the shoulder for more than 3 months;
- Full layer tendon tear of 1-5cm or full layer or complete tear of supraspinatus and/or infraspinatus tendon;
- History of non-surgical treatment failure;
- Understand the purpose of the trial, cooperate with surgical treatment and follow-up, voluntarily participate in the trial and sign an informed consent form;
- Intraoperative:
- Confirmed as a full-thickness tear of 1-5cm on the rotator cuff;
- Tendons can cover more than 50% of the humeral greater tuberosity of the shoulder joint.
You may not qualify if:
- \. Pregnant and lactating women; 2.Individuals with contraindications for surgery or anesthesia, as well as those who are allergic to known ingredients of implanted products; 3. Unable to undergo MRI examination due to claustrophobia and other reasons; 4. Individuals with a history of rotator cuff repair on the affected side, or combined with other bone, joint, or muscle soft tissue injuries in the same limb; 5.Patients with subscapular muscle injury; 6.Those with any combination of diseases or symptoms that may affect the evaluation of efficacy, such as Hamada classification of grade 3 shoulder joint disease; 7.Those with residual rotator cuff tendon fatty infiltration ≥ grade 3 by Goutallier classification; 8.Individuals who have taken oral steroids or received steroid injections within 6 weeks prior to surgery; 9.Those who have participated in other interventional clinical trials within the past 3 months prior to the conduct of this trial; 10. Researchers believe that clinical trial participants who are not suitable for participation include but are not limited to those with uncontrolled blood sugar levels, heavy drinkers, smokers, and others who affect repair and healing.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
The Second Affiliated Hospital of Zhejiang University School of Medicine
Hangzhou, Zhejiang, China
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- phase 2
- Allocation
- NA
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR INVESTIGATOR
- PI Title
- Director of Sports Medicine Department, the Second Affiliated Hospital of Zhejiang University School of Medicine
Study Record Dates
First Submitted
December 19, 2024
First Posted
January 9, 2025
Study Start
December 19, 2024
Primary Completion
December 19, 2025
Study Completion (Estimated)
December 19, 2026
Last Updated
January 9, 2025
Record last verified: 2024-12